Provexis PLC - Half-year Financial Report
Provexis plc
UNAUDITED INTERIM RESULTS FOR SIX MONTHS TO
Provexis plc ("Provexis" or the "Company"), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces its unaudited interim results for the six months ended
Highlights
· Total revenue for the period
· On
· The Company has taken orders for and / or has sold several hundred thousand pounds of Fruitflow II SD in the current period after
· In this favourable context the Company is now planning with its outsourced supply chain partners to undertake at least three further production runs of Fruitflow II SD in the next twelve months, the first of which is currently expected to be delivered in
· The planned launch by BYHEALTH, a circa
· BYHEALTH continues to work on an extensive regulatory submission to the Chinese SAMR, seeking to establish a new permitted health function claim for foods such as Fruitflow that can demonstrate an anti-platelet effect. BYHEALTH has stated publicly that it has invested 'tens of millions of funds' (RMB) in the research and development work. The Company and BYHEALTH entered into a supply and distribution agreement for Fruitflow in 2021 and the parties remain in close and constructive dialogue, at a high level. The Company will provide shareholders with as much information as it can on the timing of this commercially sensitive and potentially transformative project, subject to the multi-party confidentiality arrangements which surround the process.
· The Company's long term commercial partnership with dsm-firmenich ('DSM') has progressed well during the period, with continuing interest from some significant global customers. The commercial partnership is based on: (i) a Premix and Market-Ready Solutions supply agreement for Fruitflow II SD; and (ii) the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans.
· Underlying operating loss* for the period of
*Loss from operations, adjusted for non-cash share-based payments of
Provexis CEO
'The Company is pleased to report on another strong period of progress.
The Company's long term commercial partnership with dsm-firmenich ('DSM') has progressed well during the period, with continuing interest from some significant global customers. The commercial partnership is based on: (i) a Premix and Market-Ready Solutions supply agreement for Fruitflow II SD; and (ii) the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans.
Provexis has been working with BYHEALTH for more than nine years to support the planned launch of a number of Fruitflow based products in the Chinese market. In
The Company has developed a strong, long lasting and wide-ranging patent portfolio for Fruitflow, and it owns outright four existing patent families for Fruitflow. The new microbiome patent application takes this to a potential total of five patent families, with potential patent protection now running out to 2042. The four existing patent families have a truly global footprint, and the Company also holds other valuable intellectual property and trade secrets for Fruitflow. The intellectual property for Fruitflow is of fundamental importance to the Company and its current and future commercial partners, to include DSM and BYHEALTH, and it underpins the numerous commercial opportunities which the Company and its partners are pursuing for Fruitflow.
On
The Company has taken orders for and / or has sold several hundred thousand pounds of Fruitflow II SD in the current period after
In this favourable context the Company is now planning with its outsourced supply chain partners to undertake at least three further production runs of Fruitflow II SD in the next twelve months, the first of which is currently expected to be delivered in
The Company expects that (i) the significant changes to the sales and supply chain structure for Fruitflow from
For further information please contact:
|
Provexis plc
|
Tel: 07490 391888 |
|
Allenby Capital Limited (Nominated Adviser and Broker)
|
Tel: 020 3328 5656
|
Chairman and CEO's statement
The Company has had an active and successful first six months of the year, and it has made further progress with the commercial prospects of its innovative, patented Fruitflow® heart-health ingredient.
DSM Nutritional Products - new agreements for Fruitflow®
Provexis entered into a long-term Alliance Agreement with DSM Nutritional Products ('DSM'), which is part of DSM-Firmenich AG, in 2010 to commercialise Fruitflow through sales as an ingredient to brand owners in the food, beverage and dietary supplement categories, with a contractual term for the Alliance Agreement which ran to
More than 100 regional consumer healthcare brands have now been launched by direct customers of DSM, and a number of further regional brands have been launched through DSM's distributor channels. An increasing number of commercial projects have been initiated by DSM with prospective customers in recent years, including some prospective customers which are part of global businesses, and the total projected annual sales value of the prospective sales pipeline for Fruitflow, which is now shared across Provexis and DSM, continues to stand at a substantial multiple of existing annual sales.
In
The Company also announced the filing of a new patent application in
Under the terms of the two new agreements with DSM, and the
· DSM's existing and prospective customers for Fruitflow as a straight ingredient (not a Premix or Market-Ready solution) transferred to become direct customers of Provexis from
· A royalty is payable to DSM on the gross profits generated from Fruitflow sales to customers transferred from DSM over the first four years of the Transfer of Business agreement. The six months ended
· A new partnership was agreed with DSM in 2022 relating to the gut microbiome patent, giving DSM preferential access to the use, marketing, and sale of Fruitflow based products which are based on the patent, subject to certain milestones which have been agreed between the parties. DSM conducted a strong launch of the new microbiome technology (www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html), with widespread trade press coverage. The technology has seen strong and ongoing interest from some significant global customers.
· Provexis is selling Fruitflow as a straight ingredient to DSM exclusively for use in DSM's Premix Solutions and Market-Ready Solutions businesses, with DSM then looking to sell the resulting Premix and Market-Ready Solutions products on to its customers. The Company looks forward to supporting DSM and its Premix and Market-Ready Solutions customers for many years to come.
From
1. Former DSM customers for Fruitflow;
2. DSM and its Premix and Market-Ready Solutions businesses, which will leverage the resources and relationships of DSM in some of the major global markets, and seek to commercialise the gut microbiome patent;
3. New customers for Fruitflow as a straight ingredient;
4. BYHEALTH and its customers, through the Company's long-term supply and distribution agreement for Fruitflow with BYHEALTH; and
5. The Group's Fruitflow+ Omega-3 dietary supplement product which is sold direct to consumers, the Group will also look to serve its Chinese Cross-Border e-commerce ('CBEC') distributor for this product in
On
The Company has taken orders for and / or has sold several hundred thousand pounds of Fruitflow II SD in the current period after
In this favourable context the Company is now planning with its outsourced supply chain partners to undertake at least three further production runs of Fruitflow II SD in the next twelve months, the first of which is currently expected to be delivered in
BYHEALTH Co., Ltd.
In
The BYHEALTH Agreement, which followed the Company's extensive work with BYHEALTH over the last nine years, took full effect from
Under the BYHEALTH Agreement Provexis is responsible for the manufacture, supply and sale of Fruitflow to BYHEALTH, and BYHEALTH is responsible for the manufacture, marketing and sale of Fruitflow based functional food and dietary supplement finished products in the Territories, through BYHEALTH's extensive sales network. BYHEALTH also has exclusive rights to act as the distributor of Fruitflow as an ingredient in the Territories.
Provexis and BYHEALTH will seek to collaborate on research and development projects which may result in the development and approval of Fruitflow as a drug, for potential sale and distribution in the Territories.
The Company and BYHEALTH remain in close and constructive dialogue, at a high level, to include joint consideration of the opportunities to file further patents in
Regulatory progress in
Provexis has been working with BYHEALTH for more than nine years to support the planned launch of a number of Fruitflow based products in the Chinese market. Clinical studies conducted in
The Chinese regulatory system for functional health food ingredients, such as Fruitflow, is governed by the State Administration for Market Regulation (the 'SAMR') and it is based on a defined list of permitted health function claims which brand owners are permitted to use on product labels.
The SAMR provides the possibility of adding new health function claims to the list, with claims needing to demonstrate a relationship between a food or nutrient and a consequent health improvement, subject to evaluation and verification by the SAMR.
SAMR certified functional health foods are required to use a blue cap / blue hat logo on their product packaging, which identifies products as approved functional health foods in
BYHEALTH has been working on an extensive regulatory submission to the SAMR seeking to establish a new permitted health function claim for foods such as Fruitflow that can demonstrate an anti-platelet effect, inhibiting platelet function and conferring beneficial health effects.
On
On
The significance of these major developments for Fruitflow in
The Company has previously stated that if BYHEALTH is successful in obtaining a new permitted health function claim in
The Company will provide shareholders with as much information as it can on the timing of this commercially sensitive and potentially transformative process, subject to the multi-party confidentiality arrangements which surround the matter.
Fruitflow+ dietary supplement products
Fruitflow+ Omega-3 is available to purchase from the Company's subscription focussed e-commerce website www.fruitflowplus.com, and from Amazon
The Fruitflow+ Omega-3 business reported sales in the period of
Fruitflow+ Omega-3 has a social media presence on Facebook www.facebook.com/FruitflowPlus, Instagram www.instagram.com/fruitflowplus and Twitter / X https://twitter.com/FruitflowPlus.
The Company is seeking to expand further its commercial activities with Fruitflow+ Omega-3 and other Fruitflow+ combination products, and it is currently in dialogue with some other potential international direct selling customers.
Intellectual property
The Company is responsible for filing and maintaining patents and trade marks for Fruitflow, and patent coverage for Fruitflow now includes the following patent families which are all owned outright by Provexis:
|
Patent family
|
Developments in the period from Sep-25 to Dec-25 |
|
Improved Fruitflow / Fruit Extracts Improved Fruitflow / Fruit Extracts, with patents granted by the European Patent Office in
Patents have been granted in twelve other major territories to include
|
Patents have been validated before national patent offices of seven European states and a
|
|
Antihypertensive (blood pressure lowering) effects This patent was originally developed in collaboration with the University of Oslo, and it has now been granted for Fruitflow in
In
|
A patent application is pending in
|
|
Fruitflow with nitrates in mitigating exercise-induced inflammation and for promoting recovery from intense exercise Patents have been granted around
Further patent protection is being sought in the
|
A patent has been allowed in
|
|
Fruitflow for air pollution The use of Fruitflow in protecting against the adverse effects of air pollution on the body's cardiovascular system.
Laboratory work has shown that Fruitflow can reduce the platelet activation caused by airborne particulate matter, such as that from diesel emissions, by approximately one third.
US, Australian, Brazilian, Indonesian, Israeli, Japanese Malaysian, Mexican,
|
Patent protection has been allowed in
|
|
Fruitflow to confer health benefits in modulating the gut microbiome of humans The Company filed a patent application in
Following the completion of the international patent procedure, applications have been filed in 16 jurisdictions (including
|
Patent applications have been filed in |
Capital structure and funding
The Company is seeking to maximise the commercial returns that can be achieved from its Fruitflow technology, and the Company's cost base and its resources continue to be very tightly managed. The Company remains keen to minimise dilution to shareholders and it is focussed on moving into profitability as Fruitflow revenues increase, but while the Company remains in a loss-making position it may need to raise funds in the future to meets its working capital requirements.
Under the terms of the DSM Transfer of Business agreement which was announced in
The Company has needed to hold Fruitflow II SD in stock from
In the year ended
In
The share issues to DSM have been of direct benefit to the Company's cash resources and net assets, and they have helped the Company to fund a new production run of Fruitflow II SD which has recently been completed by the Company's outsourced supply chain partners for Fruitflow.
The Company received delivery of the new batch of Fruitflow II SD in
The Company is dealing with numerous sales enquiries from existing and new customers for further direct sales of Fruitflow in 2026 and beyond, in which favourable context the Company is now planning with its outsourced supply chain partners to undertake at least three further production runs of Fruitflow II SD in the next twelve months. The magnitude and timing of these production runs will be determined with reference to (i) estimated customer demand over the subsequent 12 to 18 months, (ii) the comparative costs and timing of a potential production run for a new batch of material and (iii) the Company's financial resources at that time.
The new production runs are likely to require a significant cash outlay, as the Company is seeking by necessity to hold greater stocks of Fruitflow to keep up with increasing demand for the product.
The Company is in ongoing dialogue with its existing and prospective customers for Fruitflow II SD, seeking their assistance as best possible with forecast volume estimates. A considerable degree of uncertainty is inherent in the forecasting process, which is subject to existing and new customers' changing plans, requirements and regulatory progress, and inevitably there is a wide range of possible outcomes in terms of overall forecast demand.
The production process for Fruitflow II SD takes place in two stages, which need to be booked with its outsourced supply chain partners well in advance of production taking place. The Company is in close dialogue with all key parties in its supply chain for Fruitflow, to include: (i) maximum capacity planning; (ii) production cost and other efficiencies; and (iii) the potential requirement for much larger batches of Fruitflow II SD to be made at relatively short notice.
With regards to sensitivity analysis, management have prepared scenario planning to stress-test potential impacts on the cash position of the business, which have included (i) different revenue outcomes, (ii) interruption of trade, (iii) no sales growth, (iv) customer failure, and (v) the possible need to pay the remaining royalties due to DSM for the two years ended
In the coming months, based on its current level of cash, the Group may therefore need to raise further equity finance or potentially new loan finance, subject in large part to (i) the size / volume of new production runs of Fruitflow II SD which the Company may need to commission, with larger production runs inevitably requiring more cash at the outset, (ii) the different revenue outcomes which may materialise and (iii) negotiations with DSM, which have yet to be concluded, regarding the royalty payments for the remaining royalty bearing period to
Considering the success of previous fundraisings and the current performance of the business, the Directors have a reasonable expectation of raising sufficient additional equity capital or new loan finance to continue in operational existence for the foreseeable future. The Company is also engaged in ongoing negotiations with a third party, potentially seeking to hold some of its future stock requirements on a consignment basis, only paying for the stock when it was required for sale.
For these reasons the Directors are of the opinion that at
Outlook
The Company is pleased to report on another strong period of progress.
The Company's long term commercial partnership with dsm-firmenich ('DSM') has progressed well during the period, with continuing interest from some significant global customers. The commercial partnership is based on: (i) a Premix and Market-Ready Solutions supply agreement for Fruitflow II SD; and (ii) the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans.
Provexis has been working with BYHEALTH for more than nine years to support the planned launch of a number of Fruitflow based products in the Chinese market. In
The Company has developed a strong, long lasting and wide-ranging patent portfolio for Fruitflow, and it owns outright four existing patent families for Fruitflow. The new microbiome patent application takes this to a potential total of five patent families, with potential patent protection now running out to 2042. The four existing patent families have a truly global footprint, and the Company also holds other valuable intellectual property and trade secrets for Fruitflow. The intellectual property for Fruitflow is of fundamental importance to the Company and its current and future commercial partners, to include DSM and BYHEALTH, and it underpins the numerous commercial opportunities which the Company and its partners are pursuing for Fruitflow.
On
The Company has taken orders for and / or has sold several hundred thousand pounds of Fruitflow II SD in the current period after
In this favourable context the Company is now planning with its outsourced supply chain partners to undertake at least three further production runs of Fruitflow II SD in the next twelve months, the first of which is currently expected to be delivered in
The Company expects that (i) the significant changes to the sales and supply chain structure for Fruitflow from
CEO Chairman
|
Consolidated statement of comprehensive income |
|
Unaudited |
Unaudited |
Audited |
|
Six months ended |
|
six months |
six months |
year |
|
|
|
ended |
ended |
ended |
|
|
|
30 September |
30 September |
31 March |
|
|
|
2025 |
2024 |
2025 |
|
|
|
£ |
£ |
£ |
|
|
Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
364,369 |
785,348 |
1,292,244 |
|
Cost of goods |
|
(194,991) |
(512,000) |
(759,304) |
|
Gross profit |
|
169,378 |
273,348 |
532,940 |
|
|
|
|
|
|
|
Selling and distribution costs |
|
(40,298) |
(32,811) |
(68,338) |
|
Research, patent and trade mark costs |
|
(108,041) |
(123,716) |
(325,625) |
|
Administrative costs - share based payment charges |
|
(154,716) |
(49,207) |
(168,317) |
|
Administrative costs - other |
|
(176,053) |
(215,153) |
(422,631) |
|
Loss from operations |
|
(309,730) |
(147,539) |
(451,971) |
|
|
|
|
|
|
|
Finance income |
|
2,584 |
890 |
2,334 |
|
Loss before taxation |
|
(307,146) |
(146,649) |
(449,637) |
|
|
|
|
|
|
|
Taxation |
|
(3,083) |
(12,500) |
(3,083) |
|
|
|
|
|
|
|
Loss and total comprehensive loss for the period |
|
(310,229) |
(159,149) |
(452,720) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
Owners of the parent |
|
(310,229) |
(159,149) |
(452,720) |
|
Loss and total comprehensive loss for the period |
|
(310,229) |
(159,149) |
(452,720) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share to owners of the parent |
|
|
|
|
|
Basic and diluted - pence |
3 |
(0.01) |
(0.01) |
(0.02) |
|
|
|
|
|
|
|
Consolidated statement of financial position |
|
Unaudited |
Unaudited |
Audited |
|
|
|
30 September |
30 September |
31 March |
|
|
|
2025 |
2024 |
2025 |
|
|
|
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
Current assets |
|
|
|
|
|
Inventories |
|
43,969 |
152,755 |
202,352 |
|
Trade and other receivables |
|
255,142 |
144,760 |
82,202 |
|
Corporation tax asset |
|
19,380 |
46,680 |
19,380 |
|
Cash and cash equivalents |
|
523,348 |
478,199 |
708,087 |
|
Total current assets |
|
841,839 |
822,394 |
1,012,021 |
|
|
|
|
|
|
|
Total assets |
|
841,839 |
822,394 |
1,012,021 |
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
(218,914) |
(471,006) |
(239,621) |
|
Current tax liabilities |
|
(12,037) |
- |
(8,585) |
|
Total current liabilities |
|
(230,951) |
(471,006) |
(248,206) |
|
|
|
|
|
|
|
Total liabilities |
|
(230,951) |
(471,006) |
(248,206) |
|
|
|
|
|
|
|
Total net assets |
|
610,888 |
351,388 |
763,815 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital and reserves attributable to |
|
|
|
|
|
owners of the parent company |
|
|
|
|
|
Share capital |
|
2,345,891 |
2,262,945 |
2,345,891 |
|
Share premium reserve |
|
19,432,882 |
18,928,940 |
19,432,882 |
|
Foreign exchange reserve |
|
2,586 |
- |
- |
|
Merger reserve |
|
6,599,174 |
6,599,174 |
6,599,174 |
|
Retained earnings |
|
(27,235,896) |
(26,905,922) |
(27,080,383) |
|
|
|
1,144,637 |
885,137 |
1,297,564 |
|
Non-controlling interest |
|
(533,749) |
(533,749) |
(533,749) |
|
Total equity |
|
610,888 |
351,388 |
763,815 |
|
Consolidated statement of cash flows |
Unaudited |
Unaudited |
Audited |
|
|
six months |
six months |
year |
|
|
ended |
ended |
ended |
|
|
30 September |
30 September |
31 March |
|
|
2025 |
2024 |
2025 |
|
|
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities |
|
|
|
|
Loss after tax |
(310,229) |
(159,149) |
(452,720) |
|
Adjustments for: |
|
|
|
|
Finance income |
(2,584) |
(890) |
(2,334) |
|
Taxation |
3,452 |
12,500 |
3,083 |
|
Share-based payment charge - share options |
154,716 |
49,207 |
168,317 |
|
Changes in inventories |
160,969 |
(16,235) |
(65,832) |
|
Changes in trade and other receivables |
(173,145) |
(19,281) |
43,682 |
|
Changes in trade and other payables |
(20,707) |
163,558 |
(67,827) |
|
Net cash flow from operations |
(187,528) |
29,710 |
(373,631) |
|
|
|
|
|
|
Taxation |
- |
(12,500) |
32,802 |
|
Total cash flow from operating activities |
(187,528) |
17,210 |
(340,829) |
|
|
|
|
|
|
Cash flow from investing activities |
|
|
|
|
Interest received |
2,789 |
890 |
1,929 |
|
Total cash flow from investing activities |
2,789 |
890 |
1,929 |
|
|
|
|
|
|
Cash flow from financing activities |
|
|
|
|
Proceeds from issue of share capital - purchase of inventory |
- |
270,742 |
857,630 |
|
Total cash flow from financing activities |
- |
270,742 |
857,630 |
|
|
|
|
|
|
Net change in cash and cash equivalents |
(184,739) |
288,842 |
518,730 |
|
Opening cash and cash equivalents |
708,087 |
189,357 |
189,357 |
|
Closing cash and cash equivalents |
523,348 |
478,199 |
708,087 |
|
Consolidated statement of changes in equity |
Share |
Share |
Foreign |
Merger |
Retained |
Total equity |
Non- |
Total |
|
|
capital |
premium |
exchange reserve |
reserve |
earnings |
attributable to owners of |
controlling interests |
equity |
|
|
|
|
|
|
|
the parent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
£ |
£ |
£ |
£ |
£ |
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At |
2,217,822 |
18,703,321 |
- |
6,599,174 |
(26,795,980) |
724,337 |
(533,749) |
190,588 |
|
|
|
|
|
|
|
|
|
|
|
Share-based charges - share options |
- |
- |
- |
- |
49,207 |
49,207 |
- |
49,207 |
|
|
|
|
|
|
|
|
|
|
|
Issue of shares - inventory purchased |
45,123 |
225,619 |
- |
- |
- |
270,742 |
- |
270,742 |
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive expense for the period |
- |
- |
- |
- |
(159,149) |
(159,149) |
- |
(159,149) |
|
|
|
|
|
|
|
|
|
|
|
At |
2,262,945 |
18,928,940 |
- |
6,599,174 |
(26,905,922) |
885,137 |
(533,749) |
351,388 |
|
|
|
|
|
|
|
|
|
|
|
Share-based charges - share options |
- |
- |
- |
- |
119,110 |
119,110 |
- |
119,110 |
|
|
|
|
|
|
|
|
|
|
|
Issue of shares - inventory purchased |
82,946 |
503,942 |
- |
- |
- |
586,888 |
- |
586,888 |
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive expense for the period |
- |
- |
- |
- |
(293,571) |
(293,571) |
- |
(293,571) |
|
|
|
|
|
|
|
|
|
|
|
At |
2,345,891 |
19,432,882 |
- |
6,599,174 |
(27,080,383) |
1,297,564 |
(533,749) |
763,815 |
|
|
|
|
|
|
|
|
|
|
|
Share-based charges - share options |
- |
- |
- |
- |
154,716 |
154,716 |
- |
154,716 |
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange reserve |
- |
- |
2,586 |
- |
- |
2,586 |
- |
2,586 |
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive expense for the period |
- |
- |
- |
- |
(310,229) |
(310,229) |
- |
(310,229) |
|
|
|
|
|
|
|
|
|
|
|
At |
2,345,891 |
19,432,882 |
2,586 |
6,599,174 |
(27,235,896) |
1,144,637 |
(533,749) |
610,888 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. General information, basis of preparation and accounting policies
General information
Provexis plc is a public limited company incorporated and domiciled in the United Kingdom (registration number 05102907). The address of the registered office is
The main activities of the Group are those of developing, licensing and selling the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.
Basis of preparation
This condensed financial information has been prepared using accounting policies consistent with International Financial Reporting Standards in the European Union (IFRS).
The same accounting policies, presentation and methods of computation are followed in this condensed financial information as are applied in the Group's latest annual audited financial statements, except as set out below. While the financial figures included in this half-yearly report have been computed in accordance with IFRS applicable to interim periods, this half-yearly report does not contain sufficient information to constitute an interim financial report as that term is defined in IAS 34.
Use of non-GAAP profit measure - underlying operating profit
The directors believe that the operating loss before share based payments measure provides additional useful information for shareholders on underlying trends and performance. This measure is used for internal performance analysis. Underlying operating loss is not defined by IFRS and therefore may not be directly comparable with other companies' adjusted profit measures. It is not intended to be a substitute for, or superior to IFRS measurements of profit.
The interim financial information does not constitute statutory accounts as defined in section 434 of the Companies Act 2006 and has been neither audited nor reviewed by the Company's auditors RPG Crouch Chapman LLP pursuant to guidance issued by the Auditing Practices Board.
The results for the year ended
The interim report for the six months ended
This announcement was approved by the Board of Provexis plc for release on
Going concern
Under the terms of the DSM Transfer of Business agreement which was announced in
The Company has needed to hold Fruitflow II SD in stock from
In the year ended
In
The share issues to DSM have been of direct benefit to the Company's cash resources and net assets, and they have helped the Company to fund a new production run of Fruitflow II SD which has recently been completed by the Company's outsourced supply chain partners for Fruitflow.
The Company received delivery of the new batch of Fruitflow II SD in
The Company is dealing with numerous sales enquiries from existing and new customers for further direct sales of Fruitflow in 2026 and beyond, in which favourable context the Company is now planning with its outsourced supply chain partners to undertake at least three further production runs of Fruitflow II SD in the next twelve months. The magnitude and timing of these production runs will be determined with reference to (i) estimated customer demand over the subsequent 12 to 18 months, (ii) the comparative costs and timing of a potential production run for a new batch of material and (iii) the Company's financial resources at that time.
The new production runs are likely to require a significant cash outlay, as the Company is seeking by necessity to hold greater stocks of Fruitflow to keep up with increasing demand for the product.
The Company is in ongoing dialogue with its existing and prospective customers for Fruitflow II SD, seeking their assistance as best possible with forecast volume estimates. A considerable degree of uncertainty is inherent in the forecasting process, which is subject to existing and new customers' changing plans, requirements and regulatory progress, and inevitably there is a wide range of possible outcomes in terms of overall forecast demand.
The production process for Fruitflow II SD takes place in two stages, which need to be booked with its outsourced supply chain partners well in advance of production taking place. The Company is in close dialogue with all key parties in its supply chain for Fruitflow, to include: (i) maximum capacity planning; (ii) production cost and other efficiencies; and (iii) the potential requirement for much larger batches of Fruitflow II SD to be made at relatively short notice.
With regards to sensitivity analysis, management have prepared scenario planning to stress-test potential impacts on the cash position of the business, which have included (i) different revenue outcomes, (ii) interruption of trade, (iii) no sales growth, (iv) customer failure, and (v) the possible need to pay the remaining royalties due to DSM for the two years ended
In the coming months, based on its current level of cash, the Group may therefore need to raise further equity finance or potentially new loan finance, subject in large part to (i) the size / volume of new production runs of Fruitflow II SD which the Company may need to commission, with larger production runs inevitably requiring more cash at the outset, (ii) the different revenue outcomes which may materialise and (iii) negotiations with DSM, which have yet to be concluded, regarding the royalty payments for the remaining royalty bearing period to
Considering the success of previous fundraisings and the current performance of the business, the Directors have a reasonable expectation of raising sufficient additional equity capital or new loan finance to continue in operational existence for the foreseeable future. The Company is also engaged in ongoing negotiations with a third party, potentially seeking to hold some of its future stock requirements on a consignment basis, only paying for the stock when it was required for sale.
For these reasons the Directors are of the opinion that at
Accounting policies
The accounting policies applied are consistent with those of the annual financial statements for the year ended
2. Segmental reporting
The Group's operating segments are determined based on the Group's internal reporting to the Chief Operating Decision Maker (CODM). The CODM has been determined to be the Board of Directors as it is primarily responsible for the allocation of resources to segments and the assessment of performance of the segments. The performance of operating segments is assessed on revenue.
The CODM uses revenue as the key measure of the segments' results as it reflects the segments' underlying trading performance for the financial period under evaluation. Revenue is reported separately to the CODM and all other reports are prepared as a single business unit.
|
Revenue |
Unaudited |
Unaudited |
Audited |
|
|
six months |
six months |
year |
|
|
ended |
ended |
ended |
|
|
30 September |
30 September |
31 March |
|
|
2025 |
2024 |
2025 |
|
|
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
Fruitflow II SD ingredient |
302,183 |
724,817 |
1,170,939 |
|
Fruitflow+ Omega-3 |
62,186 |
60,531 |
121,305 |
|
|
364,369 |
785,348 |
1,292,244 |
3. Earnings per share
Basic earnings per share amounts are calculated by dividing the profit attributable to owners of the parent by the weighted average number of ordinary shares in issue during the period.
The loss attributable to equity holders of the Company for the purpose of calculating the fully diluted loss per share is identical to that used for calculating the basic loss per share. The exercise of share options or warrants would have the effect of reducing the loss per share and is therefore anti-dilutive under the terms of IAS 33 'Earnings per Share'.
Basic and diluted loss per share amounts are in respect of all activities.
There were 288,230,000 share options and warrants in issue at
|
|
Unaudited |
Unaudited |
Audited |
|
|
six months |
six months |
year |
|
|
ended |
ended |
ended |
|
|
30 September |
30 September |
31 March |
|
|
2025 |
2024 |
2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss for the period attributable to owners of the parent - £ |
310,229 |
159,149 |
452,720 |
|
|
|
|
|
|
Weighted average number of shares |
2,345,891,239 |
2,261,712,366 |
2,284,370,301 |
|
|
|
|
|
|
Basic and diluted loss per share - pence |
0.01 |
0.01 |
0.02 |
4. Share capital and Total Voting Rights
At
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
5. Cautionary statement
This document contains certain forward-looking statements with respect to the financial condition, results and operations of the business. These statements involve risk and uncertainty as they relate to events and depend on circumstances that will incur in the future. Nothing in this interim report should be construed as a profit forecast.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE